The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials

Category Primary study
JournalMULTIPLE SCLEROSIS JOURNAL
Year 2022
This article has no abstract
Epistemonikos ID: 0287f454e0da3239d58b81d91c772f873d7f8ac9
First added on: Nov 22, 2025